Voyager Therapeutics (NASDAQ:VYGR) Cut to Strong Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded Voyager Therapeutics from “sell” to “strong sell.” Analyst sentiment is mixed overall, with MarketBeat reporting a “Moderate Buy” consensus and a $16.50 average price target.
• For its latest reported quarter, Voyager posted an adjusted loss of $0.40 per share, slightly better than estimates, but revenue of $0.61 million was far below the $6.35 million expected.
• Shares opened at $1.86, near the stock’s one-year low of $1.68 and below its 50-day and 200-day moving averages.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other research analysts have also recently issued reports about the company. HC Wainwright reissued a "buy" rating on shares of Voyager Therapeutics in a research note on Thursday, August 27th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Voyager Therapeutics in a research note on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $16.50.

Voyager Therapeutics Stock Up 8.4%

Shares of Voyager Therapeutics stock opened at $1.86 on Friday. Voyager Therapeutics has a one year low of $1.68 and a one year high of $5.48. The business has a 50-day simple moving average of $2.55 and a 200 day simple moving average of $3.41.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.01. The business had revenue of $0.61 million for the quarter, compared to analyst estimates of $6.35 million. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%. Research analysts anticipate that Voyager Therapeutics will post -1.63 EPS for the current year.

Hedge Funds Weigh In On Voyager Therapeutics

Several large investors have recently added to or reduced their stakes in VYGR. Opaleye Management Inc. lifted its holdings in Voyager Therapeutics by 3.0% in the second quarter. Opaleye Management Inc. now owns 1,185,000 shares of the company's stock valued at $4,148,000 after buying an additional 35,000 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Voyager Therapeutics in the second quarter worth $73,000. Spark Investment Management LLC purchased a new stake in shares of Voyager Therapeutics in the second quarter valued at approximately $47,000. Seven Fleet Capital Management LP boosted its position in Voyager Therapeutics by 100.0% during the second quarter. Seven Fleet Capital Management LP now owns 230,406 shares of the company's stock worth $772,000 after purchasing an additional 115,203 shares in the last quarter. Finally, Bank of America Corp DE purchased a new stake in shares of Voyager Therapeutics during the second quarter worth $158,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company aims to address conditions affecting the central nervous system by using adeno-associated virus (AAV) gene-delivery technologies to deliver therapeutic genes to targeted areas of the brain and nervous system.

Voyager's research platform, known as TRACER, is designed to identify AAV capsids with improved ability to cross the blood-brain barrier and reach the central nervous system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.